Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250873 | 0.77 | PLAAT3 (0.58) | ALDH1A1HPGDSMN1; SMN2KMT2APOLB | |
| SCHEMBL18281767 | 0.76 | L3MBTL1 (0.69) | ALDH1A1LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL14672313 | 0.74 | HSP90AA1 (0.58) | ALDH1A1HPGDKMT2AMEN1RAB9A | |
| SCHEMBL9342625 | 0.73 | MEN1 (0.55) | ALDH1A1LMNAKMT2AMEN1RAB9A | |
| SCHEMBL14702014 | 0.73 | ALDH1A1 (0.72) | ALDH1A1LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL12473135 | 0.73 | MEN1 (0.72) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23124836 | 0.72 | L3MBTL1 (0.50) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL26988416 | 0.72 | PLAAT3 (0.54) | ALDH1A1HPGDSMN1; SMN2KMT2APOLB | |
| SCHEMBL1694370 | 0.72 | L3MBTL1 (0.62) | ALDH1A1LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL16980130 | 0.72 | MEN1 (0.55) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3880664-A1 | LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ALDH1A1 122/4885LMNA 455/4885HPGD 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.